Obesity treatment: novel peripheral targets
- PMID: 20002077
- PMCID: PMC2810794
- DOI: 10.1111/j.1365-2125.2009.03522.x
Obesity treatment: novel peripheral targets
Abstract
Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon-like peptide-1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short-term food intake. These hormones therefore represent potential targets in the development of novel anti-obesity drugs. This review focuses on the role of gut hormones in short- and long-term regulation of food intake, and on the current state of development of gut hormone-based obesity therapies.
Similar articles
-
Gut hormones: implications for the treatment of obesity.Pharmacol Ther. 2009 Oct;124(1):44-56. doi: 10.1016/j.pharmthera.2009.06.005. Epub 2009 Jun 26. Pharmacol Ther. 2009. PMID: 19560488 Review.
-
Gut hormones as potential new targets for appetite regulation and the treatment of obesity.Drugs. 2008;68(2):147-63. doi: 10.2165/00003495-200868020-00002. Drugs. 2008. PMID: 18197723 Review.
-
Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.Pharmacol Res Perspect. 2024 Aug;12(4):e1243. doi: 10.1002/prp2.1243. Pharmacol Res Perspect. 2024. PMID: 39016695 Free PMC article. Review.
-
Gut hormones as peripheral anti obesity targets.Curr Drug Targets CNS Neurol Disord. 2004 Oct;3(5):379-88. doi: 10.2174/1568007043336950. Curr Drug Targets CNS Neurol Disord. 2004. PMID: 15544446 Review.
-
Gut hormones and the control of appetite.Trends Endocrinol Metab. 2004 Aug;15(6):259-63. doi: 10.1016/j.tem.2004.06.002. Trends Endocrinol Metab. 2004. PMID: 15358278 Review.
Cited by
-
Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):141-6. doi: 10.1073/pnas.1216801110. Epub 2012 Dec 17. Proc Natl Acad Sci U S A. 2013. PMID: 23248313 Free PMC article.
-
Cichoriin, a Biocoumarin, Mitigates Oxidative Stress and Associated Adverse Dysfunctions on High-Fat Diet-Induced Obesity in Rats.Life (Basel). 2022 Oct 28;12(11):1731. doi: 10.3390/life12111731. Life (Basel). 2022. PMID: 36362887 Free PMC article.
-
GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.Br J Pharmacol. 2012 May;166(1):121-36. doi: 10.1111/j.1476-5381.2011.01537.x. Br J Pharmacol. 2012. PMID: 21671898 Free PMC article. Review.
-
Comparative efficiency and safety of pharmacological approaches to the management of obesity.Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S349-54. doi: 10.2337/dc11-s255. Diabetes Care. 2011. PMID: 21525481 Free PMC article. No abstract available.
-
Unraveling oxyntomodulin, GLP1's enigmatic brother.J Endocrinol. 2012 Dec;215(3):335-46. doi: 10.1530/JOE-12-0368. Epub 2012 Sep 27. J Endocrinol. 2012. PMID: 23019069 Free PMC article. Review.
References
-
- WHO Global Infobase team. The suRF Report 2. Surveillance of Chronic Disease Risk Factors: Country-Level Data and Comparable Estimates. Geneva: World Health Organisation; 2007.
-
- Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:1723–7. - PubMed
-
- de Looper M, Bhatia K. Australian Health Trends 2001. Canberra: Australian Institute of Health and Welfare; 2001. AIHW Cat. No. PHE 24.
-
- National Audit Office. Tackling obesity in England. London: The Stationery Office; 2001. Report by the Comptroller and Auditor General.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical